HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels

Background and Objectives Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. W...

ver descrição completa

Detalhes bibliográficos
Autores: López Dupla, Miguel, Maymó Masip, Elsa, Martínez Chamorro, Esteban José, Domingo, Pere (Domingo Pedrol), Leal, Manuel, Peraire, Joaquim, Viladés, Consuelo, Veloso, Sergi, Arnedo, Mireia, Ferrando-Martínez, Sara, Beltrán-Debón, Raúl, Alba, Verónica, Gatell, José M., Vendrell, Joan, Vidal Marsal, Francisco, Chacón, Matilde R.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/100401
Acesso em linha:https://hdl.handle.net/2445/100401
Access Level:acceso abierto
Palavra-chave:Síndrome de lipodistròfia associada a VIH
VIH (Virus)
Antiretrovirals
Obesitat
Estudi de casos
HIV-associated lipodystrophy syndrome
HIV (Viruses)
Antiretroviral agents
Obesity
Case studies
Descrição
Resumo:Background and Objectives Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. We sought to explore the relationship between HALS and circulating levels of soluble (s) TWEAK and its scavenger receptor sCD163. Methods This was a cross-sectional multicenter study of 120 HIV-1-infected patients treated with a stable HAART regimen; 56 with overt HALS and 64 without HALS. Epidemiological and clinical variables were determined. Serum levels of sTWEAK and sCD163 levels were measured by ELISA. Results were analyzed with Student's t-test, Mann-Whitney U and χ2 test. Pearson and Spearman correlation were used to estimate the strength of association between variables. Results Circulating sTWEAK was significantly decreased in HALS patients compared with non-HALS patients (2.81±0.2 vs. 2.94±0.28 pg/mL, p = 0.018). No changes were observed in sCD163 levels in the studied cohorts. On multivariate analysis, a lower log sTWEAK concentration was independently associated with the presence of HALS (OR 0.027, 95% CI 0.001-0.521, p = 0.027). Conclusions HALS is associated with decreased sTWEAK levels.